VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections

VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio

Signant Health names new clinical vice president, Internal Medicine

RTI International wins FDA approval for pretomanid for treating drug-resistant TB

First Patient Enrolled in CARES10, a Phase 3, Multi-Center Study to Assess a 10 % Intravenous Immunoglobulin in Adults with Primary Immunodeficiency Disease

Tivic Health announces USD8m from Series Seed Round

Dr. Reddy's Launches OTC, Store-Brand Equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets in the US Market

LifeMax Receives Rare Pediatric Disease Designation for LM-030 for the Treatment of Netherton Syndrome

First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

Dr. Reddy's Launches Over-the-Counter Store Brand Equivalent of Mucinex D Extended Release Tablets in Two Strengths in the US Market

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study

Vedanta enrols first patient in Phase 1b/2 clinical study of VE416

Modag Launches Out of Stealth Mode with series A Financing of EUR 12 m to Develop Treatments for Parkinsonian Disorders, Including Multiple System Atrophy

LifeMax Receives Orphan Drug Designation from the United States Food and Drug Administration For LM-030 For The Treatment of Netherton Syndrome